Impact BioMedical, INC. Payments for (Proceeds from) Investments
Impact BioMedical, INC. (IBO) reported Payments for (Proceeds from) Investments of $65.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-20.
Discontinued › Cash Flow
us-gaap:PaymentsForProceedsFromInvestments · last filed 2024-02-20
- Impact BioMedical, INC. payments for (proceeds from) investments for the quarter ending 2022-12-31 was $0.00.
- Impact BioMedical, INC. payments for (proceeds from) investments for the quarter ending 2022-09-30 was $0.00.
- Impact BioMedical, INC. payments for (proceeds from) investments for fiscal 2022 was $65.00K.
| Period end | Payments for (Proceeds from) Investments 3 month | Payments for (Proceeds from) Investments 6 month | Payments for (Proceeds from) Investments 9 month | Payments for (Proceeds from) Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $65.00K 10-K · filed 2024-02-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $65.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $65.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |